ASH: With PhIII data in hand, Atara eyes a submission to treat a small but desperate group of transplant patients

Nicole DeFeudis

Editor

After more than two decades in the clinic, Atara Biotherapeutics’ T cell therapy tabelecleucel is finally headed to the FDA — but not without a pivotal …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

ASH: With PhIII data in hand, Atara eyes a submission to treat a small but desperate group of transplant patients

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Post-Hoc: Pharma CEOs' alternative reality with Trump

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

FDA lifts hold on Entrada's Duchenne drug after two years

How AI can address ongoing challenges in the life sciences industry

ASH: With PhI­II da­ta in hand, Atara eyes a sub­mis­sion to treat a small but des­per­ate group of trans­plant pa­tients

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

ASH: With PhIII data in hand, Atara eyes a submission to treat a small but desperate group of transplant patients